Dermira Inc. reported positive top-line results from its phase III ATMOS-1 and ATMOS-2 pivotal trials for DRM04 (glycopyrronium tosylate), a topical candidate for patients with excessive underarm sweating, also known as primary axillary hyperhidrosis.